$86.7 M

MACK Mkt cap, 26-Feb-2021
Merrimack Pharmaceuticals Net income (Q3, 2020)-1 M
Merrimack Pharmaceuticals EBIT (Q3, 2020)-1 M
Merrimack Pharmaceuticals Cash, 30-Sept-202015.8 M

Merrimack Pharmaceuticals Income Statement

Annual

USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

48.9m47.8m102.8m89.3m144.3m

Revenue growth, %

115%(13%)62%

Cost of goods sold

46.0k6.9m

Gross profit

89.2m137.4m

Gross profit Margin, %

100%95%

R&D expense

125.9m147.1m138.5m161.0m160.9m67.3m50.0m11.1m

General and administrative expense

15.8m21.2m30.5m57.8m80.7m28.5m15.6m16.2m

Operating expense total

141.7m168.3m169.0m218.8m247.5m105.3m65.6m27.3m

EBIT

(92.7m)(120.5m)(66.3m)(129.6m)(110.1m)(95.8m)(65.6m)(22.4m)

EBIT margin, %

(190%)(252%)(64%)(145%)(76%)

Interest expense

553.0k10.9m18.2m2.9m

Interest income

184.0k166.0k114.0k99.0k276.0k895.0k1.3m777.0k

Pre tax profit

(118.4m)(68.5m)(22.7m)

Income tax expense

(42.4m)(7.7m)(1.5m)

Net Income

(91.3m)(130.9m)(83.3m)(148.0m)(151.7m)472.0m(40.5m)(17.3m)

Quarterly

USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

11.3m12.1m11.3m14.7m18.5m6.9m13.0m27.8m28.0m14.8m36.6m16.4m21.3m33.7m28.1m

Cost of goods sold

711.0k1.9m1.0m

Gross profit

20.6m31.8m27.1m

Gross profit Margin, %

97%94%96%

R&D expense

31.7m28.8m30.9m37.0m42.5m37.6m30.3m33.8m43.6m35.7m42.8m37.8m32.9m41.0m32.1m21.6m19.8m13.6m13.1m13.7m13.0m6.4m4.7m

General and administrative expense

3.7m3.6m4.3m4.9m5.1m5.2m6.2m7.9m8.1m9.2m12.3m17.0m17.8m20.7m18.0m5.6m14.8m3.4m4.3m3.5m3.8m3.7m5.9m1.9m1.2m1.0m

Operating expense total

35.4m32.4m35.2m41.9m47.6m42.8m36.5m41.7m51.7m44.9m55.1m54.7m50.7m61.7m50.9m27.2m34.5m17.0m17.4m17.2m16.7m10.0m10.7m1.9m1.2m1.0m

EBIT

(24.0m)(20.3m)(23.9m)(27.3m)(29.1m)(35.9m)(23.5m)(13.9m)(23.7m)(30.0m)(18.6m)(38.3m)(30.1m)(29.9m)(23.9m)(27.2m)(34.5m)(17.0m)(17.4m)(17.2m)(16.7m)(10.0m)(9.3m)204.0k(1.2m)(1.0m)

EBIT margin, %

(212%)(168%)(211%)(186%)(158%)(524%)(180%)(50%)(85%)(202%)(51%)(233%)(141%)(89%)(85%)

Interest expense

1.0k1.2m1.3m406.0k578.0k403.0k414.0k172.0k

Interest income

9.0k54.0k64.0k52.0k35.0k36.0k35.0k20.0k7.0k47.0k34.0k13.0k72.0k122.0k64.0k14.0k382.0k250.0k275.0k282.0k306.0k365.0k207.0k45.0k3.0k1.0k

Pre tax profit

(59.9m)(7.5m)(17.8m)(17.1m)

Income tax expense

(30.2m)(2.1m)(4.8m)

Net Income

(23.3m)(20.0m)(23.2m)(28.2m)(30.1m)(39.6m)(27.6m)(18.1m)(27.9m)(34.8m)(22.8m)(42.6m)(38.5m)(50.7m)(30.1m)(29.7m)511.6m3.1m(17.8m)(17.8m)4.0m(10.5m)(9.4m)(705.0k)249.0k(1.2m)(1.0m)

Merrimack Pharmaceuticals Balance Sheet

Annual

USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

37.7m65.1m35.7m185.6m21.5m93.4m20.1m16.6m

Accounts Receivable

9.3m5.9m3.3m6.5m17.5m100.0k

Prepaid Expenses

9.0m5.5m4.7m5.5m1.4m4.2m2.1m

Inventories

3.7m14.6m

Current Assets

128.3m166.6m132.1m201.4m57.4m95.0m76.1m18.7m

PP&E

6.3m13.4m14.5m21.9m15.8m6.5m2.3m

Goodwill

3.6m3.6m3.6m3.6m3.6m

Total Assets

149.0m192.4m158.7m234.9m81.5m117.3m88.5m20.1m

Accounts Payable

283.0k1.9m2.5m5.0m2.9m1.0m271.0k

Dividends Payable

28.0k

Short-term debt

8.2m13.3m

Current Liabilities

38.5m57.7m111.1m103.7m88.2m19.8m14.8m2.8m

Long-term debt

103.4m106.8m257.7m216.9m14.9m

Total Debt

103.4m120.2m257.7m216.9m14.9m

Total Liabilities

155.4m235.5m260.7m418.6m334.1m21.0m29.7m2.8m

Common Stock

958.0k1.0m1.1m1.2m1.3m1.3m1.3m

Additional Paid-in Capital

434.7m527.8m552.0m617.1m702.4m577.7m580.8m556.6m

Retained Earnings

(442.1m)(572.2m)(655.2m)(802.2m)(954.8m)(482.8m)(523.3m)(540.6m)

Total Equity

(6.5m)(43.5m)(102.1m)(183.9m)96.3m58.8m17.3m

Debt to Equity Ratio

-2.4 x-1.4 x0.3 x

Debt to Assets Ratio

0.5 x1.1 x2.7 x0.2 x

Financial Leverage

-22.9 x-4.4 x-1.6 x-1.3 x1.2 x1.5 x1.2 x

Quarterly

USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

30.6m32.0m27.9m28.4m30.9m105.5m66.9m77.8m100.3m28.8m33.7m56.4m48.2m21.5m36.5m17.2m135.5m107.2m34.3m22.5m49.8m36.5m36.9m20.9m18.0m15.7m15.8m

Accounts Receivable

6.0m6.9m6.1m9.8m14.5m8.8m12.2m6.6m2.6m4.2m1.8m2.1m15.6m19.3m22.2m43.0k43.0k190.0k

Prepaid Expenses

6.5m6.6m11.3m10.2m9.2m8.9m2.5m4.4m5.8m3.2m5.4m6.4m4.5m4.6m4.1m2.3m5.9m8.0m844.0k1.7m1.8m4.6m2.1m1.5m1.9m3.6m2.9m

Inventories

8.1m12.3m14.8m

Current Assets

45.8m120.3m104.1m106.8m85.9m200.3m138.9m103.8m162.1m99.3m74.9m70.9m160.7m119.0m89.6m46.3m141.6m115.6m77.1m61.7m87.3m63.7m42.6m22.4m20.0m19.4m18.7m

PP&E

5.2m5.0m4.8m7.3m8.2m11.5m13.8m13.7m14.3m15.7m18.3m20.0m20.8m19.6m17.6m12.9m11.2m10.2m5.4m4.1m3.2m1.0m

Goodwill

3.6m3.6m3.6m3.6m3.6m3.6m3.6m3.6m3.6m3.6m3.6m3.6m3.6m3.6m3.6m

Total Assets

64.4m138.7m123.2m127.3m107.3m224.2m165.0m129.8m188.6m127.0m105.0m102.7m192.9m150.0m118.4m68.6m213.5m197.8m97.5m80.2m103.9m74.4m45.0m24.8m21.3m19.7m19.0m

Accounts Payable

2.6m2.7m771.0k6.5m4.7m7.4m5.5m4.3m2.6m9.7m6.8m6.2m10.8m12.0m8.1m7.5m8.3m8.8m2.6m1.8m953.0k841.0k24.0k710.0k839.0k208.0k50.0k

Dividends Payable

261.0k88.0k28.0k28.0k

Short-term debt

10.0k12.0m11.1m15.2m1.1m1.5m

Current Liabilities

24.8m26.7m28.2m48.3m57.7m60.9m57.0m90.9m121.2m103.7m108.6m95.3m97.4m90.9m88.3m108.0m57.7m34.6m17.5m17.9m22.1m11.8m4.9m4.7m3.3m2.3m2.2m

Long-term debt

101.8m105.1m103.4m122.1m123.1m126.3m259.8m215.5m216.9m218.0m48.9m49.9m14.8m13.5m

Total Debt

10.0k101.8m105.1m103.4m122.1m123.1m126.3m259.8m215.5m216.9m218.0m48.9m49.9m14.8m15.0m

Total Liabilities

108.1m105.6m110.2m159.5m165.7m240.9m230.8m206.9m288.5m255.8m248.1m243.3m410.1m351.6m345.6m345.8m109.0m86.2m18.2m18.0m36.9m25.4m5.0m4.7m3.3m2.3m2.2m

Common Stock

119.0k935.0k940.0k959.0k964.0k1.0m1.0m1.0m1.1m1.1m1.1m1.2m1.2m1.3m1.3m1.3m1.3m1.3m1.3m1.3m1.3m1.3m1.3m1.3m1.3m1.3m1.3m

Additional Paid-in Capital

61.7m426.0m429.2m437.3m441.3m522.7m532.8m539.8m545.1m559.2m567.8m612.1m622.4m688.8m693.4m707.4m578.1m580.1m578.5m579.3m580.0m581.4m581.9m562.6m557.1m557.5m557.9m

Retained Earnings

(374.1m)(394.1m)(417.3m)(470.3m)(500.4m)(540.0m)(599.8m)(617.9m)(645.8m)(689.5m)(712.2m)(754.4m)(840.7m)(891.5m)(921.5m)(984.5m)(472.9m)(469.8m)(500.6m)(518.3m)(514.3m)(533.7m)(543.2m)(543.9m)(540.4m)(541.5m)(542.5m)

Total Equity

(312.3m)32.7m12.8m(32.1m)(58.1m)(16.3m)(66.0m)(77.1m)(99.7m)(129.2m)(143.3m)(141.1m)(217.2m)(201.4m)(226.8m)(275.7m)106.5m111.6m79.3m62.3m67.0m49.0m40.0m20.1m18.0m17.3m16.7m

Debt to Equity Ratio

-1.5 x-1.4 x-1 x-0.9 x-0.9 x-0.9 x-1.2 x-1.1 x-1 x-0.8 x0.5 x0.4 x

Debt to Assets Ratio

0.6 x0.8 x0.5 x1 x1.2 x1.2 x1.3 x1.4 x1.8 x3.2 x0.2 x0.3 x

Financial Leverage

-0.2 x4.2 x9.6 x-4 x-1.8 x-13.8 x-2.5 x-1.7 x-1.9 x-1 x-0.7 x-0.7 x-0.9 x-0.7 x-0.5 x-0.2 x2 x1.8 x1.2 x1.3 x1.5 x1.5 x1.1 x1.2 x1.2 x1.1 x1.1 x

Merrimack Pharmaceuticals Cash Flow

Quarterly

USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

(23.3m)(43.3m)(66.5m)(28.2m)(58.2m)(98.3m)(27.8m)(46.0m)(74.1m)(34.4m)(57.3m)(99.7m)(38.7m)(89.6m)(119.9m)(30.2m)480.7m483.8m(17.8m)(35.6m)(31.6m)(10.5m)(19.9m)(20.6m)249.0k(914.0k)(1.9m)

Depreciation and Amortization

1.4m2.2m3.0m700.0k1.3m1.9m886.0k2.2m2.8m1.1m2.1m4.3m1.5m3.0m5.2m1.2m2.1m2.8m1.2m2.3m3.2m1.2m2.2m2.2m

Accounts Receivable

1.4m486.0k1.4m(531.0k)(5.3m)432.0k(6.3m)(748.0k)4.1m(935.0k)1.7m1.3m(9.2m)(12.8m)(15.7m)232.0k232.0k85.0k

Inventories

(4.4m)(8.4m)(10.7m)

Accounts Payable

(2.1m)(1.9m)(3.9m)6.9m11.4m19.7m(4.5m)(6.0m)(2.1m)4.6m7.5m335.0k(1.2m)(7.1m)(2.4m)8.1m2.5m(3.1m)(2.4m)(2.0m)1.1m(4.5m)(9.9m)(10.1m)215.0k(435.0k)(496.0k)

Cash From Operating Activities

(19.4m)(40.4m)(60.4m)(21.2m)(45.4m)(67.7m)(31.4m)(64.2m)(3.1m)(35.1m)(59.7m)(102.0m)(53.5m)(104.4m)(139.3m)(10.2m)(95.5m)(121.1m)(17.3m)(33.6m)(46.7m)(13.7m)(25.5m)(28.7m)(1.0m)(3.0m)(2.8m)

Purchases of PP&E

(326.0k)(891.0k)(1.4m)(2.4m)(3.3m)(9.1m)(1.4m)(3.0m)(4.7m)(1.2m)(4.1m)(8.1m)(1.2m)(2.0m)(2.9m)(290.0k)(287.0k)(729.0k)(16.0k)(118.0k)(118.0k)

Cash From Investing Activities

(426.0k)(74.8m)(59.8m)11.5m37.4m(13.7m)31.1m71.7m31.1m24.0m49.9m73.8m(85.5m)(63.3m)(15.0m)(290.0k)515.8m511.4m(41.8m)(37.4m)(11.8m)30.1m58.3m64.8m2.5m2.1m2.1m

Long-term Borrowings

(38.0k)(48.0k)(48.0k)(175.0m)(175.0m)(15.0m)(15.0m)(56.0k)

Dividends Paid

(4.0m)(4.2m)(3.0k)(7.0k)(140.0m)(140.0m)(20.0m)

Cash From Financing Activities

(70.0k)96.8m97.7m411.0k1.3m149.2m2.1m5.2m7.3m4.3m7.8m48.9m1.6m3.6m5.2m6.1m(306.3m)(304.5m)14.6m(16.0m)(35.9m)(56.0k)

Net Change in Cash

(19.9m)(18.4m)(22.5m)(9.3m)(6.8m)67.7m1.8m12.7m35.2m(6.9m)(2.0m)20.7m(137.4m)(164.1m)(149.1m)(4.4m)114.0m85.7m(59.2m)(71.0m)(43.8m)16.5m16.8m195.0k1.4m(845.0k)(766.0k)

Interest Paid

998.0k2.1m2.8m3.8m4.9m8.8m3.9m4.9m8.8m2.8m12.5m13.9m1.4m28.9m30.3m235.0k361.0k1.4m1.4m

Income Taxes Paid

6.1m10.0k

Merrimack Pharmaceuticals Ratios

USDQ1, 2012

Financial Leverage

-0.2 x

Merrimack Pharmaceuticals Employee Rating

345 votes
Culture & Values
3.7
Work/Life Balance
4
Senior Management
2.9
Salary & Benefits
3.5
Career Opportunities
3
Source